## Supplementary Materials: Rational Design of Toxoid Vaccine Candidates for *Staphylococcus aureus* Leukocidin AB (LukAB)

Shweta Kailasan, Thomas Kort, Ipsita Mukherjee, Grant C. Liao, Tulasikumari Kanipakala, Nils Williston, Nader Ganjbaksh, Arundhathi Venkatasubramaniam, Frederick W. Holtsberg, Hatice Karauzum, Rajan P. Adhikari and M. Javad Aman

**Table S1.** Comparison of expression using pET Duet versus pET24a (+) dual plasmid system.

Vector	IPTG Concentration (mM)	Growth/ Induction Temperature (°C)	Total Yield (mg/L)	EC50 from PMN-Based Toxicity Assay (nM)
pET Duet	0.3	37/25	19.84	0.1
pET24a(+)	0.3	37/25	20.5	0.09

Abbreviations: IPTG (Isopropyl  $\beta$ -D-1-thiogalactopyranoside); PMN (Polymononuclear neutrophils)

Table S2. Bacterial Strains.

Strain	Genotype/Description	Source
JE2	USA300 WT from Nebraska mutant library	NARSA repository
MRSA252, MN8, NCTC 8325, MRSACOL, USA200, USA100, MNHOCH	Standard SA strain	NARSA repository
MRSA ST-80	Standard SA strain	From Dr. Jean Lee, BWH, Harvard University
USA300 (NRS384)	Community MRSA strain	NARSA repository
USA1000, SF8300 and isogenic LukAB mutant	Community MRSA strain and it's isogenic LukAB mutant	From Dr. Binh Diep, UCSF

Abbreviations: SA (Staphylococcus aureus); MRSA (multi-drug resistant SA)

## **LukA**wt LukB<sub>wt</sub> MIKQLYKNIT ICTLALSTTF TVLPATSFAK MKNKKRVLIA SSLSCAILLL SAATTOANSA 33 INSEIKQVSE KNLDGDTKMY TRTATTSDSQ **FK**DSODONKK EHVDKSOOKD KRNVTNKDKN 31 \*\*\*\*\*\*\* :\*\*\*\* \*\*\*. \* \* \*:\*\*\* :\*\* \*\*\*: .\*\*\* \*\*\*\* \*\*\*\* STAPDDIGKN GKITKRTETV YDEKTNILQN 63 KNITQSLQFN FLTEPNYDKE TVFIKAKGTI \* . ::\* \*\* \*\*\*\*\*\*\* \*\*:\*\*\*\*\* \*\*\*\*\*:\*\* \*:\*: \*\*\*\* \*\*:\*\* \*\*\* LQFDFIDDPT YDKNVLLVKK QGSIHSNLKF 93 GSGLRILDPN GYWNSTLRWP GSYSVSIQNV \* \*\*\*\*\* \* ESHKEEKNSN WLKYPSEYHV DFQVKRNRKT DDNNNTNVTD FAPKNQDESR EVKYTYGYKT ::\* :\*:\*\*: \* \*\*\*.\*\*\* EILDQLPKNK ISTAKVDSTF SYSSGGKFDS 153 GGD<mark>FSINRGG LT</mark>GNITKESN YSETISYQQP 1.51 \*\*\*:\*\* \*\*\* \*\*\* <mark>\*</mark>\*:.\*\* \*\*\*\*.\*\*\*\* TKGIGRTSSN SYSKTISYNQ QNYDTIASGK 183 SYRTLLDOST SHKGVGWKVE AHLINNMGHD 181 NNNWHVHWSV IANDLKYGGE VKNRNDELLF HTRQLTNDSD NRTKS<mark>E</mark>IFSL T<mark>R</mark>NGNLWAKD 213 211 \*\*\*\*\*\*\* \*\*\*\*\* \*\* \*\* \*\* . . \*\* \*\* YRNTRIATVE NPELSFASKY RYPALVRSGF 243 NFTPKD<mark>K</mark>MPV TVSEGFNPEF LAVMSHDKKD 241 \*\*\*:\*\*\*\*\* \*\*\*\*\*\*\* \* \*\*\* \*:\*: \* .\*\*\* \*::\*\*\*\*\* NPEFLTYLSN EKSNEKTQFE VTYTRNQDIL KGKSQFVVHY KRSMDEFKID WNRHGFWGYW \*\*\*\*\* :\*\*\*:\*\*\*\* \*\* :\*\*\*\*:\* \*\*\*\*\*\*\* KNRPGIHYAP PILEKNKDGQ RLIVTYEVDW 303 SGENHVDKKE EKLSALYEVD WKTHNVKFVK \* \*\*\*\*:\*\* \*\*\*\*\*\* \*\*\*\* \*\*\* KNKTVKVVDK YSDDNKPYKE G 324 VLNDNEKK 331 :\*:\* \*.\*\*\* ::\*:: :: .

Figure S1. Key residue mutations within LukAB. LukAwt and LukBwt sequences from USA300 strain are shown along with specific mutated residues highlighted in yellow. For LukB, residues crossed out indicate deletion mutations and those colored in blue were substituted with the corresponding residues in HlgB (AEGKITPVSVKKVDDKVTLYKTTATADSD). The leader or signal sequence is shown in bold & italics. Additionally, conservation of residues within LukAwt and LukBwt variants derived from different strains for which annotated genome data is available is shown below the residues as calculated from a multiple sequence alignment using ClustalOmega (Ref). The symbols indicate conservation of: a single residue (\*), between groups of strongly similar properties - scoring  $\leq$  0.5 in the Gonnet PAM 250 matrix (:), and between groups of weakly similar properties - scoring  $\leq$  0.5 in the Gonnet PAM 250 matrix (.).




Figure S2. Expression of CD11b and/or CD14 on (A) PMN and (B) THP-1 cells.